Jason R. StubbsJared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas and Division of Nephrology & Hypertension, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas
James B. WetmoreChronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota and Division of Nephrology, Hennepin County Medical Center, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota
ItanoY, KatoS, TsuboiM, KasugaH, TsurutaY, SatoF, et al.: A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET Trial). Kidney Int Rep5: 2168–2177, 2020PubMed
ItanoY, KatoS, TsuboiM, KasugaH, TsurutaY, SatoF, et al.: A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET Trial). Kidney Int Rep 5: 2168–2177, 2020PubMed)| false
ShojiT, NakataniS, KabataD, MoriK, ShintaniA, YoshidaH, et al.: Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism: A randomized clinical trial. Clin J Am Soc Nephrol16: 599–612, 2021PubMed
ShojiT, NakataniS, KabataD, MoriK, ShintaniA, YoshidaH, et al.: Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism: A randomized clinical trial. Clin J Am Soc Nephrol 16: 599–612, 2021PubMed)| false
DörrK, KammerM, Reindl-SchwaighoferR, LorenzM, PrikoszovichT, MarculescuR, et al.: Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis. Circ Res128: 1616–1625, 2021PubMed
DörrK, KammerM, Reindl-SchwaighoferR, LorenzM, PrikoszovichT, MarculescuR, et al.: Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis. Circ Res 128: 1616–1625, 2021PubMed)| false
KaraboyasA, MuenzD, FullerDS, DesaiP, LinTC, RobinsonBM, et al.: Etelcalcetide utilization, dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients. Am J Kidney Dis79: 362–373, 2022PubMed
KaraboyasA, MuenzD, FullerDS, DesaiP, LinTC, RobinsonBM, et al.: Etelcalcetide utilization, dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients. Am J Kidney Dis 79: 362–373, 2022PubMed)| false
YokoyamaK, FukagawaM, ShigematsuT, AkibaT, YoshikawaK, TsuchiyaA, et al.: Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: Results of a post-marketing surveillance in Japan. Clin Exp Nephrol25: 66–79, 2021PubMed
YokoyamaK, FukagawaM, ShigematsuT, AkibaT, YoshikawaK, TsuchiyaA, et al.: Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: Results of a post-marketing surveillance in Japan. Clin Exp Nephrol 25: 66–79, 2021PubMed)| false
GoodmanWG, WardDT, MartinKJ, DrayerD, MooreC, XuJ, et al.: Activation of the calcium receptor by calcimimetic agents is preserved despite modest attenuating effects of hyperphosphatemia. J Am Soc Nephrol33: 201–212, 2022PubMed
GoodmanWG, WardDT, MartinKJ, DrayerD, MooreC, XuJ, et al.: Activation of the calcium receptor by calcimimetic agents is preserved despite modest attenuating effects of hyperphosphatemia. J Am Soc Nephrol 33: 201–212, 2022PubMed)| false
DamrathJG, MoeSM, WallaceJM: Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease. J Bone Miner Res37: 1297–1306, 2022PubMed
DamrathJG, MoeSM, WallaceJM: Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease. J Bone Miner Res 37: 1297–1306, 2022PubMed)| false
BernardorJ, FlammierS, RanchinB, GaillardS, PlatelD, PeyruchaudO, et al.: Inhibition of osteoclast differentiation by 1.25-D and the calcimimetic KP2326 reveals 1.25-D resistance in advanced CKD. J Bone Miner Res35: 2265–2274, 2020PubMed
BernardorJ, FlammierS, RanchinB, GaillardS, PlatelD, PeyruchaudO, et al.: Inhibition of osteoclast differentiation by 1.25-D and the calcimimetic KP2326 reveals 1.25-D resistance in advanced CKD. J Bone Miner Res 35: 2265–2274, 2020PubMed)| false
Díaz-TocadosJM, Rodríguez-OrtizME, AlmadénY, PinedaC, Martínez-MorenoJM, HerenciaC, et al.: Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int95: 1064–1078, 2019PubMed
Díaz-TocadosJM, Rodríguez-OrtizME, AlmadénY, PinedaC, Martínez-MorenoJM, HerenciaC, et al.: Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int 95: 1064–1078, 2019PubMed)| false
ImafukuT, TanakaM, TokunagaK, MiyamuraS, KatoH, TanakaS, et al.: Effect of cinacalcet on the redox status of albumin in secondary hyperparathyroidism patients receiving hemodialysis. Biol Pharm Bull43: 1583–1590, 2020PubMed
ImafukuT, TanakaM, TokunagaK, MiyamuraS, KatoH, TanakaS, et al.: Effect of cinacalcet on the redox status of albumin in secondary hyperparathyroidism patients receiving hemodialysis. Biol Pharm Bull 43: 1583–1590, 2020PubMed)| false
HaarhausM, EvenepoelP; European Renal Osteodystrophy (EUROD) workgroup; Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA): Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int100: 546–558, 2021PubMed
HaarhausM, EvenepoelP; European Renal Osteodystrophy (EUROD) workgroup; Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA): Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int 100: 546–558, 2021PubMed)| false
ChenCL, ChenNC, WuFZ, WuMT: Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study. Osteoporos Int31: 1507–1516, 2020PubMed
ChenCL, ChenNC, WuFZ, WuMT: Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: A pilot study. Osteoporos Int 31: 1507–1516, 2020PubMed)| false
OttSM, MallucheHH, JorgettiV, ElderGJ: Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney Int100: 502–505, 2021PubMed
OttSM, MallucheHH, JorgettiV, ElderGJ: Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney Int 100: 502–505, 2021PubMed)| false
van der PlasW, KruijffS, SidhuSB, DelbridgeLW, SywakMS, EngelsmanAF: Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease. Surgery169: 275–281, 2021PubMed
van der PlasW, KruijffS, SidhuSB, DelbridgeLW, SywakMS, EngelsmanAF: Parathyroidectomy for patients with secondary hyperparathyroidism in a changing landscape for the management of end-stage renal disease. Surgery 169: 275–281, 2021PubMed)| false
ZhangDL, ChenS, GaoMZ, LinYC, HongFY, YouZH, et al.: Ultrasound-guided radiofrequency ablation: A new attempt to the treatment of refractory hyperparathyroidism secondary to chronic kidney disease. Kidney Int Rep7: 282–288, 2021PubMed
ZhangDL, ChenS, GaoMZ, LinYC, HongFY, YouZH, et al.: Ultrasound-guided radiofrequency ablation: A new attempt to the treatment of refractory hyperparathyroidism secondary to chronic kidney disease. Kidney Int Rep 7: 282–288, 2021PubMed)| false
ZhaoS, GanW, XieW, CaoJ, ZhangL, WenP, et al.: A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: A retrospective study. Ren Fail44: 23–29, 2022PubMed
ZhaoS, GanW, XieW, CaoJ, ZhangL, WenP, et al.: A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: A retrospective study. Ren Fail 44: 23–29, 2022PubMed)| false
IshaniA, LiuJ, WetmoreJB, LoweKA, DoT, BradburyBD, et al.: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol10: 90–97, 2015PubMed
IshaniA, LiuJ, WetmoreJB, LoweKA, DoT, BradburyBD, et al.: Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 10: 90–97, 2015PubMed)| false
Williams-KarneskyRL, KrumeichL, WachtelH, FrakerDL, WirtallaC, VenutoFA, et al.: Data to inform counseling on parathyroidectomy for secondary hyperparathyroidism of renal origin. Surgery171: 63–68, 2022PubMed
Williams-KarneskyRL, KrumeichL, WachtelH, FrakerDL, WirtallaC, VenutoFA, et al.: Data to inform counseling on parathyroidectomy for secondary hyperparathyroidism of renal origin. Surgery 171: 63–68, 2022PubMed)| false
PhimphilaiM, InyaS, ManosroiW: A predictive risk score to diagnose hypocalcemia after parathyroidectomy in patients with secondary hyperparathyroidism: A 22-year retrospective cohort study. Sci Rep12: 9548, 2022PubMed
PhimphilaiM, InyaS, ManosroiW: A predictive risk score to diagnose hypocalcemia after parathyroidectomy in patients with secondary hyperparathyroidism: A 22-year retrospective cohort study. Sci Rep 12: 9548, 2022PubMed)| false
SiqueiraFR, OliveiraKC, DominguezWV, TruytsCAM, MoysésRMA, Dos ReisLM, et al.: Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism. Eur J Clin Nutr75: 1126–1133, 2021PubMed
SiqueiraFR, OliveiraKC, DominguezWV, TruytsCAM, MoysésRMA, Dos ReisLM, et al.: Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism. Eur J Clin Nutr 75: 1126–1133, 2021PubMed)| false
BozicM, Diaz-TocadosJM, Bermudez-LopezM, FornéC, MartinezC, FernandezE, et al.: Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: An analysis from the NEFRONA cohort. Nephrol Dial Transplant37: 663–672, 2022PubMed
BozicM, Diaz-TocadosJM, Bermudez-LopezM, FornéC, MartinezC, FernandezE, et al.: Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: An analysis from the NEFRONA cohort. Nephrol Dial Transplant 37: 663–672, 2022PubMed)| false
KomabaH, ZhaoJ, YamamotoS, NomuraT, FullerDS, McCulloughKP, et al.: Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: Results from the DOPPS. J Cachexia Sarcopenia Muscle12: 855–865, 2021PubMed
KomabaH, ZhaoJ, YamamotoS, NomuraT, FullerDS, McCulloughKP, et al.: Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: Results from the DOPPS. J Cachexia Sarcopenia Muscle 12: 855–865, 2021PubMed)| false
EgstrandS, NordholmA, MorevatiM, MaceML, HassanA, Naveh-ManyT, et al.: A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder. Kidney Int98: 1461–1475, 2020PubMed
EgstrandS, NordholmA, MorevatiM, MaceML, HassanA, Naveh-ManyT, et al.: A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder. Kidney Int 98: 1461–1475, 2020PubMed)| false
EgstrandS, MaceML, MorevatiM, NordholmA, EngelholmLH, ThomsenJS, et al.: Hypomorphic expression of parathyroid Bmal1 disrupts the internal parathyroid circadian clock and increases parathyroid cell proliferation in response to uremia. Kidney Int101: 1232–1250, 2022PubMed
EgstrandS, MaceML, MorevatiM, NordholmA, EngelholmLH, ThomsenJS, et al.: Hypomorphic expression of parathyroid Bmal1 disrupts the internal parathyroid circadian clock and increases parathyroid cell proliferation in response to uremia. Kidney Int 101: 1232–1250, 2022PubMed)| false
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL, et al.: Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med168: 422–430, 2018PubMed
KettelerM, BlockGA, EvenepoelP, FukagawaM, HerzogCA, McCannL, et al.: Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: Synopsis of the kidney disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med 168: 422–430, 2018PubMed)| false
SciallaJJ, KendrickJ, UribarriJ, KovesdyCP, GutiérrezOM, JimenezEY, et al.: State-of-the-art management of hyperphosphatemia in patients with CKD: An NKF-KDOQI controversies perspective. Am J Kidney Dis77: 132–141, 2021PubMed
SciallaJJ, KendrickJ, UribarriJ, KovesdyCP, GutiérrezOM, JimenezEY, et al.: State-of-the-art management of hyperphosphatemia in patients with CKD: An NKF-KDOQI controversies perspective. Am J Kidney Dis 77: 132–141, 2021PubMed)| false
SampsonM, FariaN, PowellJJ; PEACH study investigators: Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: A randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease. Nephrol Dial Transplant36: 1399–1407, 2021PubMed
SampsonM, FariaN, PowellJJ; PEACH study investigators: Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: A randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease. Nephrol Dial Transplant 36: 1399–1407, 2021PubMed)| false
LarssonTE, KameokaC, NakajoI, TaniuchiY, YoshidaS, AkizawaT, et al.: NPT-IIb inhibition does not improve hyperphosphatemia in CKD. Kidney Int Rep3: 73–80, 2017PubMed
LarssonTE, KameokaC, NakajoI, TaniuchiY, YoshidaS, AkizawaT, et al.: NPT-IIb inhibition does not improve hyperphosphatemia in CKD. Kidney Int Rep 3: 73–80, 2017PubMed)| false
ChengSC, YoungDO, HuangY, DelmezJA, CoyneDW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol3: 1131–1138, 2008PubMed
ChengSC, YoungDO, HuangY, DelmezJA, CoyneDW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3: 1131–1138, 2008PubMed)| false
YoungDO, ChengSC, DelmezJA, CoyneDW: The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int29: 562–567, 2009PubMed
YoungDO, ChengSC, DelmezJA, CoyneDW: The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 29: 562–567, 2009PubMed)| false
IxJH, IsakovaT, LariveB, RaphaelKL, RajDS, CheungAK, et al.: Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol30: 1096–1108, 2019PubMed
IxJH, IsakovaT, LariveB, RaphaelKL, RajDS, CheungAK, et al.: Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol 30: 1096–1108, 2019PubMed)| false
KettelerM, WiecekA, RosenkranzAR, PaschA, RekowskiJ, HellmannB, et al.: Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis—A randomized clinical trial. Kidney Int Rep6: 594–604, 2020PubMed
KettelerM, WiecekA, RosenkranzAR, PaschA, RekowskiJ, HellmannB, et al.: Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis—A randomized clinical trial. Kidney Int Rep 6: 594–604, 2020PubMed)| false
KettelerM, WiecekA, RosenkranzAR, OseC, RekowskiJ, LorenzH, et al.: Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase III randomised controlled NOPHOS trial [published online ahead of print Jun 25, 2022]. Nephrol Dial Transplant doi:10.1093/ndt/gfac206PubMed
KettelerM, WiecekA, RosenkranzAR, OseC, RekowskiJ, LorenzH, et al.: Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase III randomised controlled NOPHOS trial [published online ahead of print Jun 25, 2022]. Nephrol Dial Transplant doi:10.1093/ndt/gfac206PubMed)| false
TsuboiY, OhtomoS, IchidaY, HagitaH, OzawaK, IidaM, et al.: EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder. Kidney Int98: 343–354, 2020PubMed
TsuboiY, OhtomoS, IchidaY, HagitaH, OzawaK, IidaM, et al.: EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder. Kidney Int 98: 343–354, 2020PubMed)| false
Hill GallantKM, StremkeER, TrevinoLL, MoorthiRN, DoshiS, WastneyME, et al.: EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney Int99: 1225–1233, 2021PubMed
Hill GallantKM, StremkeER, TrevinoLL, MoorthiRN, DoshiS, WastneyME, et al.: EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney Int 99: 1225–1233, 2021PubMed)| false
KingAJ, SiegelM, HeY, NieB, WangJ, Koo-McCoyS, et al.: Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med10: eaam6474, 2018PubMed
KingAJ, SiegelM, HeY, NieB, WangJ, Koo-McCoyS, et al.: Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med 10: eaam6474, 2018PubMed)| false
PergolaPE, RosenbaumDP, YangY, ChertowGM: A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J Am Soc Nephrol32: 1465–1473, 2021PubMed
PergolaPE, RosenbaumDP, YangY, ChertowGM: A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J Am Soc Nephrol 32: 1465–1473, 2021PubMed)| false
ChazotG, LemoineS, KocevarG, KalbacherE, Sappey-MarinierD, RouvièreO, et al.: Intracellular phosphate and ATP depletion measured by magnetic resonance spectroscopy in patients receiving maintenance hemodialysis. J Am Soc Nephrol32: 229–237, 2021PubMed
ChazotG, LemoineS, KocevarG, KalbacherE, Sappey-MarinierD, RouvièreO, et al.: Intracellular phosphate and ATP depletion measured by magnetic resonance spectroscopy in patients receiving maintenance hemodialysis. J Am Soc Nephrol 32: 229–237, 2021PubMed)| false
StremkeER, TrevinoL, DoshiS, MoorthiRN, Hill GallantKM, MoeSM: Postdialysis serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders. Hemodial Int26: 255–263, 2022PubMed
StremkeER, TrevinoL, DoshiS, MoorthiRN, Hill GallantKM, MoeSM: Postdialysis serum phosphate equilibrium in hemodialysis patients on a controlled diet and no binders. Hemodial Int 26: 255–263, 2022PubMed)| false
TiongMK, CaiMMX, ToussaintND, TanSJ, PaschA, SmithER: Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Sci Rep12: 7358, 2022PubMed
TiongMK, CaiMMX, ToussaintND, TanSJ, PaschA, SmithER: Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Sci Rep 12: 7358, 2022PubMed)| false
ToussaintND, PedagogosE, LioufasNM, ElderGJ, PascoeEM, BadveSV, et al.; IMPROVE-CKD Trial Investigators: A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol31: 2653–2666, 2020PubMed
ToussaintND, PedagogosE, LioufasNM, ElderGJ, PascoeEM, BadveSV, et al.; IMPROVE-CKD Trial Investigators: A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol 31: 2653–2666, 2020PubMed)| false
LioufasNM, PascoeEM, HawleyCM, ElderGJ, BadveSV, BlockGA, et al.: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol33: 59–76, 2022PubMed
LioufasNM, PascoeEM, HawleyCM, ElderGJ, BadveSV, BlockGA, et al.: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol 33: 59–76, 2022PubMed)| false
SimicP, KimW, ZhouW, PierceKA, ChangW, SykesDB, et al.: Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest130: 1513–1526, 2020PubMed
SimicP, KimW, ZhouW, PierceKA, ChangW, SykesDB, et al.: Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest 130: 1513–1526, 2020PubMed)| false
Courbon G, Francis C, Gerber C, Neuburg S, Wang X, Lynch E, et al.: Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone Res 9: 35, 2021 PubMed
59.
McKnightQ, JenkinsS, LiX, NelsonT, MarlierA, CantleyLG, et al.: IL-1β drives production of FGF-23 at the onset of chronic kidney disease in mice. J Bone Miner Res35: 1352–1362, 2020PubMed
McKnightQ, JenkinsS, LiX, NelsonT, MarlierA, CantleyLG, et al.: IL-1β drives production of FGF-23 at the onset of chronic kidney disease in mice. J Bone Miner Res 35: 1352–1362, 2020PubMed)| false
HumaldaJK, YeungSMH, GeleijnseJM, GijsbersL, RiphagenIJ, HoornEJ, et al.: Effects of potassium or sodium supplementation on mineral homeostasis: A controlled dietary intervention study. J Clin Endocrinol Metab105: e3246–e3256, 2020PubMed
HumaldaJK, YeungSMH, GeleijnseJM, GijsbersL, RiphagenIJ, HoornEJ, et al.: Effects of potassium or sodium supplementation on mineral homeostasis: A controlled dietary intervention study. J Clin Endocrinol Metab 105: e3246–e3256, 2020PubMed)| false
SharmaS, KatzR, GinsbergC, BullenA, VallonV, ThomsonS, et al.: Renal clearance of fibroblast growth factor-23 (FGF23) and its fragments in humans. J Bone Miner Res37: 1170–1178, 2022PubMed
SharmaS, KatzR, GinsbergC, BullenA, VallonV, ThomsonS, et al.: Renal clearance of fibroblast growth factor-23 (FGF23) and its fragments in humans. J Bone Miner Res 37: 1170–1178, 2022PubMed)| false
WangAA, CaiX, SrivastavaA, PrasadPV, SpragueSM, CarrJ, et al.: Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney3603: 258–268, 2021PubMed
WangAA, CaiX, SrivastavaA, PrasadPV, SpragueSM, CarrJ, et al.: Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360 3: 258–268, 2021PubMed)| false
KomabaH, FullerDS, TaniguchiM, YamamotoS, NomuraT, ZhaoJ, et al.: Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns study. Kidney Int Rep5: 1956–1964, 2020PubMed
KomabaH, FullerDS, TaniguchiM, YamamotoS, NomuraT, ZhaoJ, et al.: Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns study. Kidney Int Rep 5: 1956–1964, 2020PubMed)| false
MehtaRC, ChoME, CaiX, LeeJ, ChenJ, HeJ, et al; CRIC Study Investigators: Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int100: 1292–1302, 2021PubMed
MehtaRC, ChoME, CaiX, LeeJ, ChenJ, HeJ, et al; CRIC Study Investigators: Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int 100: 1292–1302, 2021PubMed)| false
De JongMA, EisengaMF, van BallegooijenAJ, BeulensJWJ, VervloetMG, NavisG, et al.: Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrol Dial Transplant36: 121–128, 2021PubMed
De JongMA, EisengaMF, van BallegooijenAJ, BeulensJWJ, VervloetMG, NavisG, et al.: Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Nephrol Dial Transplant 36: 121–128, 2021PubMed)| false
El TersM, LuP, MahnkenJD, StubbsJR, ZhangS, WallaceDP, et al.: Prognostic value of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease. Kidney Int Rep6: 953–961, 2021PubMed
El TersM, LuP, MahnkenJD, StubbsJR, ZhangS, WallaceDP, et al.: Prognostic value of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease. Kidney Int Rep 6: 953–961, 2021PubMed)| false
IsakovaT, CaiX, LeeJ, MehtaR, ZhangX, YangW, et al; CRIC Study Investigators: Longitudinal evolution of markers of mineral metabolism in patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis75: 235–244, 2020PubMed
IsakovaT, CaiX, LeeJ, MehtaR, ZhangX, YangW, et al; CRIC Study Investigators: Longitudinal evolution of markers of mineral metabolism in patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 75: 235–244, 2020PubMed)| false
IshigamiJ, GramsME, MichosED, LutseyPL, MatsushitaK: 25-hydroxyvitamin D, fibroblast growth factor 23, and risk of acute kidney injury over 20 years of follow-up. Kidney Int Rep6: 1299–1308, 2021PubMed
IshigamiJ, GramsME, MichosED, LutseyPL, MatsushitaK: 25-hydroxyvitamin D, fibroblast growth factor 23, and risk of acute kidney injury over 20 years of follow-up. Kidney Int Rep 6: 1299–1308, 2021PubMed)| false
DesbiensLC, SidibéA, UngRV, Mac-WayF: FGF23-Klotho axis and fractures in patients without and with early CKD: A case-cohort analysis of CARTaGENE. J Clin Endocrinol Metab107: e2502–e2512, 2022PubMed
DesbiensLC, SidibéA, UngRV, Mac-WayF: FGF23-Klotho axis and fractures in patients without and with early CKD: A case-cohort analysis of CARTaGENE. J Clin Endocrinol Metab 107: e2502–e2512, 2022PubMed)| false
Hughes-AustinJM, KatzR, SembaRD, KritchevskySB, BauerDC, SarnakMJ, et al.: Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab105: e2903–e2911, 2020PubMed
Hughes-AustinJM, KatzR, SembaRD, KritchevskySB, BauerDC, SarnakMJ, et al.: Biomarkers of bone turnover identify subsets of chronic kidney disease patients at higher risk for fracture. J Clin Endocrinol Metab 105: e2903–e2911, 2020PubMed)| false
